February 26, 2021
It’s no secret that Click Therapeutics is on a roll with pharma partnerships. The mental health-focused digital therapeutic company made headlines this week when it announced a new clinical trial with Japanese pharma company Otsuka, based on a deal made in 2019.
But this isn't the only deal the New York-based company worked on with the life science industry. In September, the company signed a $...
February 24, 2021
All around the world the coronavirus pandemic has led to an uptick in digital healthcare delivery models. While telemedicine is often touted as the poster child of digital success in 2020, digital therapeutics (DTx) also emerged as a player on the global stage.
"What we are seeing is digital therapeutics, while they won’t directly treat COVID, they are really an integral component of this...
February 24, 2021
Otsuka Pharmaceutical and Click Therapeutics have announced the launch of a new, fully remote clinical trial being conducted on Verily's Project Baseline platform.
Called the Mirai study, it will be measuring a digital therapeutics intervention's effectiveness in reducing symptoms of depression among adults who have a major depressive disorder (MDD) diagnosis and are on antidepressant monotherapy...
February 16, 2021
Pharma giant AstraZeneca is teaming up with AliveCor, maker of artificial intelligence-enabled personal ECG devices, in an effort to study new ways of managing cardio, renal and metabolic issues.
The partnership will revolve around AliveCor’s Kardia-K AI, which is designed to analyze ECGs in order to measure a patient’s potassium levels without needing to draw blood from the patient. Specifically...
February 16, 2021
Italian startup PatchAi has joined forces with pharma giant Roche to launch a digital solution for patients affected by oncological diseases.
PatchAi for Smart Health Companion (SHC) embeds a virtual assistant which engages patients through empathic conversations using artificial intelligence (AI) and machine learning.
Following a pilot of the platform in July last year, it is now available to...
February 12, 2021
Digital therapeutics have been plodding on a steady path toward acceptance within healthcare, but the modality reached new heights during a year of unprecedented adoption for digital health technologies. More and more software-based treatments are picking up regulatory approvals – including three De Novo clearances in 2020 alone – while the ongoing COVID-19 pandemic has exposed more consumers,...
February 3, 2021
Highmark, a Blue Cross Blue Shield-affiliated health insurer, will expand access to Freespira's digital therapeutic for PTSD, panic disorder, panic attacks and other panic symptoms.
In addition to bringing the treatment to members living in Pennsylvania, Delaware and West Virginia, the agreement will also provide remote coaching on how to use Freespira to those not already receiving support from...
February 2, 2021
January 29, 2021
The alarming scale of the opioid use disorder (OUD) epidemic has resulted in unprecedented human and economic devastation, and there is significant opportunity for digital tools to alter the gold standard of care to one that is ongoing and on-demand.
The epidemic has only worsened since the onset of COVID-19, given heightened economic instability, social isolation, disruption to transportation...
January 28, 2021
23andMe's new COVID-19 resource. Consumer genomics company 23andMe has released a new interactive tool that allows users to see how various health factors could impact the risk of COVID-19 hospitalization. The COVID-19 Severity Calculator pulls data from the company's COVID-19 study, which included 10,000 participants diagnosed with the disease and 750 who were hospitalized.
23andMe warned that...